RU2318516C2 - Method for treating male patients for erectile dysfunction - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: method involves applying phosphodiesterase type 5 inhibitor in combination with Papaverin hydrochloride or Pentoxifilline. Single dose of Sildenafil citrate 10 mg or Tadalafil 3 mg are used as phosphodiesterase type 5 inhibitors. Papaverin hydrochloride is introduced as single dose of 40 mg and Pentoxifilline at a dose of 100 mg.

EFFECT: improved genital blood circulation; reduced risk of adverse side effects.

Description

The invention relates to medicine, namely to sexopathology.

There is a method of treating erectile dysfunction by administering pharmacotherapy using drugs from the group of type 5 phosphodiesterase inhibitors: sildenafil citrate (25-100 mg), tadalafil (20 mg) situationally before sexual intercourse (Russian Drug Register "Drug Encyclopedia", M. , 2006, p. 162, 724, 761).

The disadvantage of this method is the presence of side effects: headache, dizziness, flushing, impaired vision, nasal congestion, ringing in the ears, arterial hypotension, tachycardia, as well as the high cost of treatment.

The technical result of the proposed solution is to reduce side effects, reduce the cost of the method, improve genital blood flow after a daily course of its use.

This result is achieved in that the funds from the group of type 5 phosphodiesterase inhibitors - sildenafil citrate, tadalafil are used in doses: sildenafil citrate 10 mg at a time, tadalafil 3 mg at a time, and one of the following vasodilators - papaverine hydrochloride is prescribed a dose of 40 mg per dose, pentoxifylline at a dose of 100 mg per dose once situationally or with a course dose for 2-4 weeks.

This result does not follow from the prior art.

The method is as follows.

Patients with erectile dysfunction are prescribed small doses of type 5 phosphodiesterase inhibitors - sildenafil citrate at a dose of 10 mg per dose, tadalafil at a dose of 3 mg per dose, and one of the following vasodilators is prescribed - papaverine hydrochloride at a dose of 40 mg per dose , pentoxifylline at a dose of 100 mg per dose once situationally or with a course dose for 2-4 weeks.

Example 1

Patient A., born in 1945, suffers from erectile dysfunction for two years. Repeatedly sought sexological help. Acceptance of drugs traditionally used in sexual practice (adaptogens, vitamins and others) did not give a positive result. Taking sildenafil citrate at a dose of 25 mg before intercourse did not lead to an improvement in erection. The intake of sildenafil citrate in a dose of 50-100 mg improved the quality of the erection, followed by successful sexual intercourse. However, the drug was accompanied by severe headaches, a rush of blood to the head, face, nasal congestion, tinnitus, impaired vision and heart palpitations. The same was observed with tadalafil in a dose of 20 mg per dose. In addition, an improvement in erection was observed only within 1-24 hours after taking the drugs. Outside of their intake, no improvement in erectile function was noted.

The patient was prescribed sildenafil citrate at a dose of 10 mg per dose and additionally papaverine hydrochloride at a dose of 40 mg per dose in a course dose for three weeks. From the third day of admission, the patient noted daily spontaneous erections and satisfactory adequate erections, allowing sexual intercourse with a regularity of 2 times a week. No side effects were observed with the proposed combination of drugs.

At a repeat visit, a month after the cessation of the proposed complex, the patient reported that the received positive effect was preserved.

Example 2

Patient V., born in 1942, suffers from erectile dysfunction for three years. The drugs traditionally used in sexological practice (adaptogens, vitamins, and others) did not produce the desired result. For 1.5 years with a regularity of 1-2 times a week, he takes tadalafil in a dose of 20 mg and conducts sexual intercourse. More often than not, it cannot purchase a drug because of its high cost. In addition, while taking the drug, there is a slight increase in heart rate and flushing.

The patient was offered tadalafil at a dose of 3 mg per dose and an additional pentoxifylline at a dose of 100 mg per dose once 1-2 hours before the intended sexual intercourse. Acceptance of the proposed combination allowed us to achieve a satisfactory adequate erection and a successful sexual intercourse. No side effects were noted.

The proposed combination of drugs allowed the patient to significantly reduce the cost of treatment and increase sexual entrepreneurship up to four times a month.

This method was applied by us to 50 patients with a positive effect in 92% of cases.

The specified method has advantages over the known, consisting in reducing the dose, the disappearance of side effects, cheaper method (2-6 times), increasing the stability of the therapeutic effect compared to known methods.

Claims (1)

A method of treating erectile dysfunction by using type 5 phosphodiesterase inhibitors, characterized in that sildenafil citrate in a single dose of 10 mg or tadalafil 3 mg is administered as such inhibitors, while papaverine hydrochloride in a single dose of 40 mg or pentoxifylline 100 mg is additionally administered.